Beyond Air, Inc. · NASDAQ:XAIR
Beyond Air — Investor Presentation (October 2024)
17 slides from Beyond Air's investor presentation, October 2024
Slide 1: Corporate Presentation
Corporate Presentation October 2024
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of Beyond Air, Inc. (the “Company”) nor shall there be any sale of securities in any
Slide 3: Executive Summary
Executive Summary Commercial stage medical device company targeting the hospital based nitric oxide (NO) market Novel, disruptive technology provides - Overall cost savings to the hospital - Safe environment for patients and hospital staff - Saves space & time - more time for direct patient care
Slide 4: Nitric Oxide Revolution
Nitric Oxide Revolution Innovative LungFit® Platform Elicits Paradigm Shift Hospital NICU* Hospital Setting+ At-Home Treatment+ High concentration nitric oxide for the High concentration nitric oxide for the treatment of lung infections treatment lung infections ® Revolutionary LungFit technology pl
Slide 5: Introducing LungFit PH with our Patented Plasma Pulse Technology
Introducing LungFit® PH with our Patented Plasma Pulse Technology LungFit® PH is the first and only FDA approved system to generate continuous, unlimited NO from room air. Oxygen 60 Watts Nitric Oxide (NO) NO2 Smart Filter Nitrogen Electrode Nitrogen Dioxide (NO2) 5 Main and Backup Generators For il
Slide 6: LungFit PH Commercial Opportunity
LungFit® PH Commercial Opportunity FDA approved for term and near-term neonates with hypoxic respiratory failure (aka persistent pulmonary hypertension of the newborn (PPHN)) US market ~$350m; Global market opportunity ~$700m – Commercial model: monthly fee for service with 1-4yr contracts – no
Slide 7: Sizing up the Nitric Oxide Competition
Sizing up the Nitric Oxide Competition VERO Biotech Linde Airgas Therapeutics Mallinckrodt Generates NO GENOSYL DS NOxBOXi Ulspira INOMAX DSIR Ambient Air Generates from N2O4 Gas Cylinders Gas Cylinders Gas Cylinders (~85 lbs) (~200 lbs) (~175 lbs) (~175 lbs) (75 lbs; 44lbs off cart) (Market Leader)
Slide 8: Why Do We Win?
Why Do We Win? iNO supply iNO storage Dose & Flow Speed to iNO delivery shutdown iNO supply Other Features predictability requirements Range Treatment and restart ® LungFit PH Filter NO2 filter Just press power Room Air change <6 switch ALWAYS None Full No water trap minutes Unlimit
Slide 9: Obstacles with Cylinders Are Real
Obstacles with Cylinders Are Real Vero’s GENOSYL, with all its drawbacks, Cylinders are a safety hazard has taken significant market share • A leak can cause unsafe levels of nitrogen (>10%) from cylinders dioxide (NO2) levels • In the Vero operating manual there are • Weight and size causes back/sh
Slide 10: LungFit PH: All You Need Is Air
LungFit® PH: All You Need Is Air ® LungFit PH uses patented Plasma Pulse Technology to generate nitric oxide within seconds from ambient air, eliminating the need for sourcing NO from cylinders or cassettes. Confidently deliver the set dose and initiate iNO therapy in < 1 minute • Significantly si
Slide 11: LungFit PH: Customer Confidence
LungFit® PH: Customer Confidence Patient Safety Post Approval Over 60 hospitals Over 1,600 patients treated Over 110,000 hours of iNO delivered And… 2 NO generators in each LungFit® PH All You Need Is Air TM 11
Slide 12: Nitric Oxide: A Magic Molecule?
Nitric Oxide A Magic Molecule?
Slide 13: Nitric Oxide: A Simple, Yet Complex Molecule
Nitric Oxide: A Simple, Yet Complex Molecule Nitric oxide synthase (NOS) exists in 3 isoforms in the human body and has multiple functions. • Nitric Oxide (NO) is the combination of Type Location Mechanism Therapeutic Target nitrogen and oxygen in a specific manner • NO is a free radical gas that th
Slide 14: LungFit For Treating Lung Infections
LungFit® For Treating Lung Infections* 5,000+ Treatments 170+ Patients 12 Different 0 Serious Adverse Administered Treated Clinical Settings Events Related to NO Chronic, Refractory Lung Infections are a Major Unmet Medical Need ® • Treatment at home with LungFit can address this >$10b market • US h
Slide 15: Financial and Patent Information
Financial and Patent Information Financial Overview Ticker XAIR >15 issued patents expiring up to 2040 Exchange NASDAQ >10 pending patent applications, if issued, may extend expiration through ® Share Price $0.39 (as of 9/30/24) 2044 (includes LungFit and UNO) Shares Patent portfolio is strong and b
Slide 16: Non-LungFit Nitric Oxide Programs
Non-LungFit® Nitric Oxide Programs Drug Therapeutic Area Preclinical Ph 1 Ph 2 Ph 3 NDA Commercial Next Milestone(*) First-in-human data nNOS Inhibitor Autism spectrum disorder (ASD) anticipated in 2026 (neuronal nitric oxide synthase inhibitor) Other nNOS related neurological disorders For more inf
Slide 17: For more information contact
For more information contact: Investor Relations IR@beyondair.net www.beyondair.net